Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tenvie Therapeutics Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 2 distinct art units. The presence of distinct examiners suggests that each pending matter is being handled by a different individual, which affects how the company's current prosecution efforts are managed. This distribution requires the applicant to maintain a legal strategy that addresses the specific procedural expectations of multiple departments simultaneously.
SHIM, DAVID M. is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. This single examiner is responsible for a portion of the company's active workload. Practitioners should note that the workload is split across different units, requiring a strategy that accounts for the specific nuances of each unit's examination standards. Successful navigation of these distinct art units will be essential for the company to secure its intellectual property within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIM, DAVID M. | 1 | 58.3% | +58.3% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041539 | COMPOUNDS, COMPOSITIONS AND METHODS | SHIM, DAVID M. | 19d overdue |
| 18001695 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDOWELL, BRIAN E | 72d |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18041539 | COMPOUNDS, COMPOSITIONS AND METHODS | SHIM, DAVID M. | 1626 | §103Other | Final Rejection | 19d overdue | Pending | Feb 13, 2023 |
| 18001695 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDOWELL, BRIAN E | 1624 | §112 | Final Rejection | 72d | Pending | Dec 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial